1,326 results on '"Bosi, Alberto"'
Search Results
202. Impact of Complete Response on Survival with Either Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Pooled Analysis of 5 Phase III Trials in Newly Diagnosed Multiple Myeloma Patients
203. Elotuzumab Plus Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: 2-Year Follow-up
204. Benda-BEAM High-Dose Therapy Prior to Auto-SCT Is Effective in Resistant/Relapsed DLBCL
205. Role of Genetic Polymorphisms on Response to R-Chopregimen in Diffuse Large B-Cell Lymphoma Patients: An Interim Analysis of a Multicenter Prospective Pharmacogenetic Study
206. The FcɛR2/CD23 antigen: A hallmark of chronic lymphocytic leukemia B cells
207. Recommendations for managing the donation of haematopoietic stem cells from related and unrelated donors for allogeneic transplantation
208. Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma.
209. Hypermethylation of Wnt antagonist gene promoters and activation of Wnt pathway in myelodysplastic marrow cells
210. Patients with ≥ 20 × 10(9)/L Platelets at Baseline May Have a Prompt Response to Romiplostim During the Early Phase of Treatment: an Italian Single-Institution Experience
211. No proinflammatory signature in CD34+ hematopoietic progenitor cells in multiple sclerosis patients
212. Treatment of lower oesophageal sphincter damage with bone marrow derived mesenchymal stem cells
213. Multilineage dysplasia as assessed by immunophenotype has no impact on clinical-biological features and outcome of NPM1-mutated acute myeloid leukemia
214. Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment
215. A randomized phase II study of bortezomib (Btz)/dexamethasone (dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
216. Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide
217. Factors Predicting Outcome after Allogeneic Stem Cell Transplantation in Primary Refractory Acute Myeloid Leukemia: A Retrospective Analysis of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO)
218. A Survey on Clinical and Biological Characteristic and Therapy Management of an Italian Series of 455 Adult Patients with Systemic Mastocytosis on Behalf of Italian Registry of Mastocytosis
219. Updating Long-Term Outcome of Intermittent Imatinib (INTERIM) Treatment in Elderly Patients with Ph+-CML
220. A Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm: A Study from the AGIMM Group
221. Impact of Mutation Status of ASXL1, EZH2, SRSF2, IDH1/2 on Clinical Phenotype and Prognosis in Patients with Post-Polycythemia and Post-Essential Thrombocythemia Myelofibrosis: An AGIMM Study
222. JAK2V617F Complete Molecular Remission in Long-Term Follow-up of Patients with Polycythemia Vera and Essential Thrombocythemia Treated with Ruxolitinib
223. Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group
224. Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project
225. Unrelated Cord Blood Versus Non-T Cell Depleted Haploidentical Stem Cell Transplantation: Comparable Results in Adults with Acute Leukemia, a Eurocord and ALWP-EBMT Study
226. Decision Driven Factors for Allopurinol Dosage in Tumor Lysis Syndrome Prophylaxis: The European Experience of the Florence Pivotal Study
227. Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasms: A Study of the AGIMM & IWG-MRT Groups in 519 Subjects
228. Decision Analysis of Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome Stratified According to the Revised International Prognostic Scoring System (IPSS-R)
229. Randomized Trial of Busulfan with Cyclophosphamide Versus Busulfan with Fludarabine As Preparative Regimen to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia: A Study from the Gruppo Italiano Trapianto Midollo Osseo (GITMO)
230. First Line Treatment with Bendamustine in Selected Non Hodgkin's Lymphoma Patients: Prospective Experience in Tuscany Region
231. Open questions in the treatment of immune thrombocytopenic purpura
232. The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils of polycythemia vera
233. Overexpression of microRNA-16-2 contributes to the abnormal erythropoiesis in polycythemia vera
234. A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-tointermediate risk acute myeloid leukemia : results from a randomized, double-blind, phase 2 tria
235. Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical Hodgkin lymphoma and correlation with early FDG-PET assessment.
236. Management of anaemia in oncohaematological patients treated with biosimilar epoetin alfa: results of an Italian observational, retrospective study.
237. Primary Cutaneous Follicular Center Cell Lymphoma: Clinical and Histological Aspects
238. Identification of pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B-cell lymphoma
239. CXCR4 expression accounts for clinical phenotype and outcome in acute myeloid leukemia
240. Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas
241. Extracorporeal photopheresis for the treatment of acute and chronic graft-versus-host disease in adults and children: best practice recommendations from an Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and Italian Group for Bone Marrow Transplantation (GITMO) consensus process
242. Diagnosis of a T-lineage acute lymphoblastic leukemia through digitalized cell analysis of the pleural effusion
243. Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome
244. Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts
245. The costs of mobilisation and collection of peripheral blood stem cells in multiple myeloma and lymphoma in an European country: Results from The Gruppo Italiano Trapianto Midollo Osseo (GITMO) and Società Italiana di Emaferesi e Manipolazione Cellulare (SIdEM) survey
246. Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis
247. The Revised International Prognostic Scoring System (IPSS-R) Predicts Posttransplantation Outcome Of Patients With Myelodysplastic Syndrome Receiving Allogeneic Stem Cell Transplantation: A Basis For Clinical Decision Making
248. Atherothrombotic Risk and TKIs Treatment In Chronic Myeloid Leukemia Patients: A Role For Genetic Predisposition and Pro-Inflammatory/Pro-Oxidative Status?
249. The Long-Term Outcome Of Adult Patients With Acute Myeloid Leukemia NPM+ and FLT3/ITD- Is Not Significantly Improved By The Application Of An Allogeneic Stem Cell Transplantation
250. Rituximab With Or Without Chlorambucil For The Treatment Of Extranodal Marginal Zone B-Cell Lymphoma (MALT Lymphoma) Results From a Monocentric Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.